Table 2.
Agreement on the use of BZD assessed by using a 10 cm line of visual analogue scale from totally disagree to totally agree*
| Issues | Totally disagree, n (%) | Disagree, n (%) | Neutral, n (%) | Agree, n (%) | Totally agree, n (%) |
| 1. For clinically significant insomnia | 2 (3.6) | 1 (1.8) | 11 (20.0) | 14 (25.5) | 27 (49.1) |
| 2. For clinically significant anxiety | 7 (12.7) | 4 (7.3) | 10 (18.2) | 15 (27.3) | 19 (34.5) |
| 3. For clinically significant depression | 16 (29.1) | 11 (20.0) | 12 (21.8) | 5 (9.1) | 11 (20.0) |
| 4. For regular use of less than 1 week | 2 (3.6) | 1 (1.8) | 8 (14.5) | 13 (23.6) | 31 (56.4) |
| 5. For regular use of 1 week – 1 month | 15 (27.3) | 2 (3.6) | 12 (21.8) | 15 (27.3) | 11 (20.0) |
| 6. For regular use of more than 1 month – 4 months | 28 (50.9) | 10 (18.2) | 8 (14.5) | 5 (9.1) | 4 (7.3) |
| 7. For regular use of more than 4 months – 6 months | 39 (70.9) | 9 (16.4) | 4 (7.3) | 1 (1.8) | 2 (3.6) |
| 8. For regular use of more than 6 months | 47 (85.5) | 4 (7.3) | 3 (5.5) | 0 (0.0) | 1 (1.8) |
*A VAS score of 0.00–1.9, 2.0–3.9, 4.0–6.0, 6.1–8.0, and 8.1–10.0 were classified as totally disagree, disagree, neutral, agree, and totally agree